543 related articles for article (PubMed ID: 16940798)
21. Shifting guidelines for myeloid growth factors: applications in cancer chemotherapy.
Daniel DB; Crawford J;
Curr Hematol Rep; 2005 Nov; 4(6):441-5. PubMed ID: 16232380
[TBL] [Abstract][Full Text] [Related]
22. [Guidelines for prevention of febrile neutropenia].
Barroso S; Damasceno M; Dinis J; Gervásio H; da Luz R; Passos-Coelho JL; Sá A; Costa L; Rodrigues H; Andrade S; Macedo A; Moital I
Acta Med Port; 2008; 21(1):7-19. PubMed ID: 18489831
[TBL] [Abstract][Full Text] [Related]
23. Optimal use of granulocyte-colony-stimulating factor in patients with cancer who are at risk for chemotherapy-induced neutropenia.
Cappozzo C
Oncol Nurs Forum; 2004 May; 31(3):569-76. PubMed ID: 15146222
[TBL] [Abstract][Full Text] [Related]
24. Optimal use of recombinant granulocyte colony-stimulating factor with chemotherapy for solid tumors.
Danova M; Barni S; Del Mastro L; Danesi R; Pappagallo GL
Expert Rev Anticancer Ther; 2011 Aug; 11(8):1303-13. PubMed ID: 21916584
[TBL] [Abstract][Full Text] [Related]
25. Pharmacologic rationale for early G-CSF prophylaxis in cancer patients and role of pharmacogenetics in treatment optimization.
Crea F; Giovannetti E; Zinzani PL; Danesi R
Crit Rev Oncol Hematol; 2009 Oct; 72(1):21-44. PubMed ID: 19111474
[TBL] [Abstract][Full Text] [Related]
26. Recombinant human granulocyte-macrophage colony-stimulating factor in combination with antibiotics in the treatment of febrile neutropenia in children.
Riikonen P
Stem Cells; 1995 May; 13(3):201-5. PubMed ID: 7613488
[TBL] [Abstract][Full Text] [Related]
27. Neutropenia management with granulocyte colony-stimulating factors: from guidelines to nursing practice protocols.
Dolan S; Crombez P; Munoz M
Eur J Oncol Nurs; 2005; 9 Suppl 1():S14-23. PubMed ID: 16207534
[TBL] [Abstract][Full Text] [Related]
28. Pegfilgrastim use during chemotherapy: current and future applications.
Wolf T; Densmore JJ
Curr Hematol Rep; 2004 Nov; 3(6):419-23. PubMed ID: 15496275
[TBL] [Abstract][Full Text] [Related]
29. Granulocytic growth factors and cancer-related neutropenia: limited effects.
Prescrire Int; 2006 Oct; 15(85):189-91. PubMed ID: 17128529
[TBL] [Abstract][Full Text] [Related]
30. Strategies for minimizing complications of neutropenia: prophylactic myeloid growth factors or antibiotics.
Wingard JR; Elmongy M
Crit Rev Oncol Hematol; 2009 Nov; 72(2):144-54. PubMed ID: 19237297
[TBL] [Abstract][Full Text] [Related]
31. Contribution of glycosylated recombinant human granulocyte colony-stimulating factor (lenograstim) use in current cancer treatment: review of clinical data.
Gunzer K; Clarisse B; Lheureux S; Delcambre C; Joly F
Expert Opin Biol Ther; 2010 Apr; 10(4):615-30. PubMed ID: 20218922
[TBL] [Abstract][Full Text] [Related]
32. [Bone marrow suppression--including guidelines for the appropriate use of G-CSF].
Watanabe T
Gan To Kagaku Ryoho; 2003 Jun; 30(6):755-9. PubMed ID: 12852340
[TBL] [Abstract][Full Text] [Related]
33. Antibiotic prophylaxis in chemotherapy-induced neutropenia: time to reconsider.
Lo N; Cullen M
Hematol Oncol; 2006 Sep; 24(3):120-5. PubMed ID: 16783844
[TBL] [Abstract][Full Text] [Related]
34. Comparative effectiveness of pegfilgrastim, filgrastim, and sargramostim prophylaxis for neutropenia-related hospitalization: two US retrospective claims analyses.
Henk HJ; Becker L; Tan H; Yu J; Kavati A; Naeim A; Deeter R; Barron R
J Med Econ; 2013; 16(1):160-8. PubMed ID: 23016568
[TBL] [Abstract][Full Text] [Related]
35. Granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, and other immunomodulatory therapies for the treatment of infectious diseases in solid organ transplant recipients.
Page AV; Liles WC
Curr Opin Organ Transplant; 2008 Dec; 13(6):575-80. PubMed ID: 19060545
[TBL] [Abstract][Full Text] [Related]
36. Prophylactic and therapeutic strategies in chemotherapy-induced neutropenia.
Saloustros E; Tryfonidis K; Georgoulias V
Expert Opin Pharmacother; 2011 Apr; 12(6):851-63. PubMed ID: 21254862
[TBL] [Abstract][Full Text] [Related]
37. Should prophylactic granulocyte-colony stimulating factor be used in multiple myeloma patients developing neutropenia under lenalidomide-based therapy?
Mateos MV; García-Sanz R; Colado E; Olazábal J; San-Miguel J
Br J Haematol; 2008 Feb; 140(3):324-6. PubMed ID: 18067473
[TBL] [Abstract][Full Text] [Related]
38. When the risk of febrile neutropenia is 20%, prophylactic colony-stimulating factor use is clinically effective, but is it cost-effective?
Adams JR; Angelotta C; Bennett CL
J Clin Oncol; 2006 Jul; 24(19):2975-7. PubMed ID: 16682722
[No Abstract] [Full Text] [Related]
39. Novel strategies for granulocyte colony-stimulating factor treatment of severe prolonged neutropenia suggested by mathematical modeling.
Shochat E; Rom-Kedar V
Clin Cancer Res; 2008 Oct; 14(20):6354-63. PubMed ID: 18927273
[TBL] [Abstract][Full Text] [Related]
40. Development and implementation of a risk assessment tool for chemotherapy-induced neutropenia.
Donohue R
Oncol Nurs Forum; 2006 Nov; 33(2):347-52. PubMed ID: 16518450
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
